Revised Adult Immunization Guideline Recommended by the Korean Society of Infectious Diseases, 2014

참고문헌 (70)

1. Vila-Corcoles A, "Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice", Drugs Aging, 30, pp.263~276 (2013)
2. Moberley S, "Vaccines for preventing pneumococcal infection in adults", Cochrane Database Syst Rev, 1 (2013)
3. Bonten M, "Community acquired pneumonia immunisation trial in adults (CAPITA)", 9th International Symposium on Pneumococci and Pneumococcal Diseases, 3, pp.95~ (2014), ISPPD
4. Jackson LA, "Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults", Vaccine, 31, pp.3577~3584 (2003)
5. Jackson LA, "Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine", Vaccine, 31, pp.3585~3593 (2013)
6. Bryant K, "Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults aged 18-49 years, naive to 23-valent pneumococcal polysaccharide vaccine", ESCMID (2013)
7. Ho YL, "Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil", Vaccine, 31, pp.4047~4053 (2013)
8. French N, "A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults", N Engl J Med, 362, pp.812~822 (2010)
9. Simonsen L, "Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis", Lancet Respir Med, 2, pp.387~394 (2014)
10. Harboe ZB, "Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality", Clin Infect Dis, 59, pp.1066~1073 (2014)
11. Centers for Disease Control and Prevention, "Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older", MMWR Morb Mortal Wkly Rep, 61, pp.394~395 (2012)
12. Centers for Disease Control and Prevention, "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Morb Mortal Wkly Rep, 61, pp.816~819 (2012)
13. Song JY, "Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study", BMC Infect Dis, 13, pp.202~ (2013)
14. Kim SH, "Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study", Antimicrob Agents Chemother, 56, pp.1418~1426 (2012)
15. Tomczyk S, "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Morb Mortal Wkly Rep, 63, pp.822~825 (2014)
16. Greenberg RN, "Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age", Vaccine, 32, pp.2364~2374 (2014)
17. Jackson LA, "Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older", Vaccine, 31, pp.3594~3602 (2013)
18. Centers for Disease Control and Prevention, "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012", MMWR Morb Mortal Wkly Rep, 62, pp.131~135 (2013)
19. Leuridan E, "Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants", Pediatr Infect Dis J, 30, pp.608~610 (2011)
20. Gall SA, "Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels", Am J Obstet Gynecol, 204, pp.334.e1~334.e5 (2011)
21. Healy CM, "Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants", Clin Infect Dis, 56, pp.539~544 (2013)
22. Zheteyeva YA, "Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women", Am J Obstet Gynecol, 207, pp.59.e1~59.e7 (2012)
23. Centers for Disease Control and Prevention, "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010", MMWR Morb Mortal Wkly Rep, 60, pp.13~15 (2011)
24. Centers for Disease Control and Prevention, "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap)vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012", MMWR Morb Mortal Wkly Rep, 61, pp.468~470 (2012)
25. Akinsanya-Beysolow I, "Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years - United States, 2014", MMWR Morb Mortal Wkly Rep, 63, pp.108~109 (2014)
26. "Pertussis (whooping cough) immunisation for pregnant women 2014"[URL]
27. "Canadian immunization guide 2013"[URL]
28. "The Australian immunisation handbook 10th Edition 2013"[URL]
29. "Disease web statistics system 2014"[URL]
30. 권효진, "Infant Pertussis and Household Transmission in Korea", Journal of Korean Medical Science, 27(12), pp.1547~1551 (2012), 대한의학회
31. Schmader KE, "Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59years", Clin Infect Dis, 54, pp.922~928 (2012)
32. Centers for Disease Control and Prevention, "Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years", MMWR Morb Mortal Wkly Rep, 60, pp.1528~ (2011)
33. Giuliano AR, "Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males", N Engl J Med, 364, pp.401~411 (2011)
34. Palefsky JM, "HPV vaccine against anal HPV infection and anal intraepithelial neoplasia", N Engl J Med, 365, pp.1576~1585 (2011)
35. Centers for Disease Control and Prevention, "Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011", MMWR Morb Mortal Wkly Rep, 60, pp.1705~1708 (2011)
36. "Global advisory committee on vaccine safety, 11-12 December 2013", Wkly Epidemiol Rec, 89, pp.53~60 (2014)
37. "Global advisory committee on vaccine safety, 12-13 June 2013", Wkly Epidemiol Rec, 88, pp.301~312 (2013)
38. "Media press release"[URL]
39. "Study Reports Aluminum in Vaccines Poses Extremely Low Risk to Infants"[URL]
40. "Global Advisory Committee on Vaccine Safety, report of meeting held 6-7 June 2012"[URL]
41. Harris JW, "Influenza occurring in pregnant women: a statistical study of thirteen hundred and fifty cases", JAMA, 72, pp.978~980 (1919)
42. Freeman DW, "Deaths from Asian influenza associated with pregnancy", Am J Obstet Gynecol, 78, pp.1172~1175 (1959)
43. Jamieson DJ, "H1N1 2009 influenza virus infection during pregnancy in the USA", Lancet, 374, pp.451~458 (2009)
44. Siston AM, "Pandemic 2009 Influenza A(H1N1) virus illness among pregnant women in the United States", JAMA, 303, pp.1517~1525 (2010)
45. Mosby LG, "2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature", Am J Obstet Gynecol, 205, pp.10~18 (2011)
46. "Vaccines against influenza WHO position paper - November 2012", Wkly Epidemiol Rec, 87, pp.461~476 (2012)
47. 김백남, "우리나라 임신부에서 대유행 인플루엔자(H1N1) 2009 감염", Infection and Chemotherapy, 43(1), pp.55~59 (2011), 대한감염학회
48. 안준환, "Was 2009 Pandemic Influenza A (H1N1) Mild Among Pregnant Korean Women?", 전남의대학술지, 49(2), pp.96~99 (2013), 의과학연구소
49. Thompson MG, "Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons", Clin Infect Dis, 58, pp.449~457 (2014)
50. Legge A, "Rates and determinants of seasonal influenza vaccination in pregnancy and association with neonatal outcomes", CMAJ, 186, pp.E157~E164 (2014)
51. Nordin JD, "Maternal influenza vaccine and risks for preterm or small for gestational age birth", J Pediatr, 164, pp.1051~1057.e2 (2014)
52. Zaman K, "Effectiveness of maternal influenza immunization in mothers and infants", N Engl J Med, 359, pp.1555~1564 (2008)
53. Kim IS, "Perception on influenza vaccination in Korean women of childbearing age", Clin Exp Vaccine Res, 1, pp.88~94 (2012)
54. 김미정, "임신부의 인플루엔자 백신 접종률 및 관련요인", Infection and Chemotherapy, 41(6), pp.349~354 (2009), 대한감염학회
55. Lee YK, "2009-2010 novel influenza A (H1N1)vaccination coverage in the Republic of Korea", Am J Infect Control, 40, pp.481~483 (2012)
56. 노지윤, "Influenza Vaccines: Unmet Needs and Recent Developments", Infection and Chemotherapy, 45(4), pp.375~386 (2013), 대한감염학회[DOI]
57. "Korean influenza surveillance report, 2012-2013"[URL]
58. "Korean influenza surveillance report, 2011-2012/:"[URL]
59. "Korean influenza surveillance report, 2010-2011"[URL]
60. Eurosurveillance editorial team, "WHO recommendations on the composition of the 2013", 14 influenza virus vaccines in the northern hemisphere, 2013, pp.18, 20411~
61. Kieninger D, "Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years", BMC Infect Dis, pp.13~343 (2013)
62. Pépin S, "Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults", Vaccine, 31, pp.5572~5578 (2013)
63. Jain VK, "Vaccine for prevention of mild and moderate-to-severe influenza in children", N Engl J Med, 369, pp.2481~2491 (2013)
64. "Disease web statistics system"[URL]
65. Kim SA, "An expanded age range for meningococcal meningitis:molecular diagnostic evidence from population-based surveillance in Asia", BMC Infect Dis, 12, pp.310~ (2012)
66. 조혜경, "The Causative Organisms of Bacterial Meningitis in Korean Children in 1996-2005", Journal of Korean Medical Science, 25(6), pp.895~899 (2010), 대한의학회
67. Cohn AC, "Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).", MMWR Recomm Rep, 62, pp.1~28 (2013)
68. Epidemiology and prevention of vaccine-preventable disease, "Korea Centers for Diseases Control and Prevention", KCDC, ~ (2013)
69. "National immunization program"[URL]
70. "Meeting of the Strategic Advisory Group of Experts on immunization, April 2013 - conclusions and recommendations", Wkly Epidemiol Rec, 88, pp.201~206 (2013)

관련 논문AI추천